Viral Hepatitis
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2005; 11(4): 488-491
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.488
Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia
Eva Zusinaite, Kaja Metsküla, Riina Salupere
Eva Zusinaite, Riina Salupere, Department of Internal Medicine, University of Tartu, Puusepa 6, Tartu 51014, Estonia
Kaja Metsküla, Chair of Immunology, Department of General and Molecular Pathology, University of Tartu, Ravila 19, Tartu 51014, Estonia
Author contributions: All authors contributed equally to the work.
Correspondence to: Eva Zusinaite, Department of Internal Medicine, University of Tartu Puusepa 6, Tartu 51014, Estonia. evazusinaite@hotmail.com
Telephone: +372-7-318607 Fax: +372-7-318607
Received: December 10, 2003
Revised: December 14, 2003
Accepted: February 11, 2004
Published online: January 28, 2005
Abstract

AIM: To determine the prevalence of several autoantibodies in chronic hepatitis C patients, and to find out whether the pattern of autoantibodies was associated with hepatitis C virus (HCV) genotypes.

METHODS: Sera from 90 consecutive patients with chronic hepatitis C were investigated on the presence of anti-nuclear (ANA), anti-mitochondrial (AMA), anti-smooth muscle (SMA), anti-liver-kidney microsomal type 1 (LKMA1), anti-parietal cell (PCA), anti-thyroid microsomal (TMA), and anti-reticulin (ARA) autoantibodies. The autoantibodies were identified by indirect immunofluorescence. HCV genotypes were determined by a restriction fragment length polymorphism analysis of the amplified 5’ noncoding genome region.

RESULTS: Forty-six (51.1%) patients were positive for at least one autoantibody. Various antibodies were presented as follows: ANA in 13 (14.4%) patients, SMA in 39 (43.3%), TMA in 2 (2.2%), and ARA in 1 (1.1%) patients. In 9 cases, sera were positive for two autoantibodies (ANA and SMA). AMA, PCA and LKMA1 were not detected in the observed sera. HCV genotypes were distributed as follows: 1b in 66 (73.3%) patients, 3a in 18 (20.0%), and 2a in 6 (6.7%) patients.

CONCLUSION: A high prevalence of ANA and SMA can be found in chronic hepatitis C patients. Autoantibodies are present at low titre (1:10) in most of the cases. Distribution of the autoantibodies show no differences in the sex groups and between patients infected with different HCV genotypes.

Keywords: Chronic hepatitis C, Autoantibodies, HCV genotypes